Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FKC289 infusion · 1 trial · 1 indication
Number of subjects experiencing DLT
Number of subjects experiencing AEs and SAEs
Number of subjects with positive detection of RCL
| Arm | Type | Description |
|---|---|---|
| FKC289 injection | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| FKC289 infusion | DRUG | Anti-BCMA/CD19 chimeric antigen receptor autologous T cells |
Inclusion Criteria: 1. Voluntarily signed the informed consent form (ICF); 2. Aged between 18-75 years old (inclusive); 3. Confirmed clinical diagnosis of primary light chain (AL) amyloidosis; 4. Relapsed or refractory disease; 5. dFLC ≥ 40 mg/L (based on central laboratory test results); 6. ECOG p...
FKC289 infusion is an investigational small molecule being studied for the treatment of relapsed or refractory Primary Light Chain (AL) Amyloidosis. It is currently in Phase 1 clinical development and has not been approved by any regulatory authority.
FKC289 infusion is being developed by Kairos Pharma, Ltd., a company listed on the stock exchange under the ticker symbol KAPA. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
FKC289 infusion is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its safety and effectiveness in patients.
FKC289 infusion is being studied in a Phase 1/II open-label, single-arm, multicenter clinical trial with the identifier NCT07765524. This trial is evaluating the drug in subjects with relapsed or refractory Primary AL Amyloidosis and is expected to enroll 32 participants in China.
FKC289 infusion is a distinct investigational drug candidate. No alternative names for this drug have been disclosed in the available clinical trial information. It is being studied under its own name in the ongoing clinical development program.